No­var­tis lays out San­doz spin­off time­line with an Oct. 4 tar­get date af­ter share­hold­er vote

Last year
R&D

AB­VC Bio­Phar­ma to break ground in Chi­na, ad­vances 20% stake in Zhonghui re­al es­tate 

Last year
R&D
China

Gilead tracks five years of HIV grant giv­ing in hard-hit US South, and dou­bles down on new ap­proach­es

Last year
Pharma
Marketing

Blue Shield of Cal­i­for­nia breaks off from phar­ma­cy ben­e­fit man­ag­er in new deal with Ama­zon and Mark Cuban

Last year
Pharma

Doc­tors With­out Bor­ders re­jects Vi­iV Health­care's pro­posed con­tract for long-act­ing HIV PrEP drug

Last year
Pharma

DOJ plans to take mifepri­s­tone chal­lenge to the Supreme Court

Last year
Pharma
FDA+

FDA is­sues rare no­tice of non­com­pli­ance for not re­port­ing clin­i­cal tri­al re­sults

Last year
FDA+

EMA re­views da­ta on risk of neu­rode­vel­op­men­tal dis­or­ders for chil­dren with fa­thers on val­proate drugs

Last year
FDA+

Fed­er­al court judge rules in fa­vor of Ot­suka's Tai­ho in Lon­surf patent suit

Last year
R&D

Bay­er's cell ther­a­py unit Blue­Rock Ther­a­peu­tics lays off about 50 em­ploy­ees

Last year
People
Cell/Gene Tx

Man­u­fac­tur­ing roundup: Au­risco com­pletes FDA in­spec­tion of in­gre­di­ent pro­duc­tion site; NIH picks Exothera to de­vel­op ...

Last year
Manufacturing

In­tel­lia, Verve run clin­i­cal tri­als abroad amid FDA’s ‘cau­tious’ ap­proach to gene edit­ing

Last year
R&D

Val­ne­va tops up loan by $100M; Ipsen gets a vouch­er

Last year
News Briefing

Se­lec­ta Bio­sciences is nar­row­ing its fo­cus

Last year
R&D

I-Mab to seek ap­proval of pe­di­atric growth hor­mone de­fi­cien­cy drug in Chi­na next year af­ter PhI­II win

Last year
R&D

SPAC Ash­ing­ton In­no­va­tion plans to ac­quire dor­mant biotech Celixir and lead heart fail­ure pro­gram for $172M

Last year
Deals
R&D

His tiny pre­na­tal test­ing com­pa­ny has big plans af­ter ex­act­ing le­gal re­venge on lab gi­ants

Last year
R&D
In Focus

Abcuro reels in $155M to test an­ti­body's po­ten­tial in rare mus­cle dis­ease, set­ting biotech's 2026 BLA plans

Last year
Financing
Startups

FDA ap­proves Ipsen's ul­tra-rare dis­ease drug palo­varotene

Last year
Pharma
FDA+

Fed­er­al ap­peals court re­stricts ac­cess to abor­tion pill, at­tempt­ing to re­vert back to FDA's 2016 re­stric­tions on the ...

Last year
FDA+
Law

Ab­b­Vie rais­es aware­ness around men­tal health and skin con­di­tions with pa­tients, docs and a celebri­ty spokesper­son

Last year
Pharma
Marketing

One year lat­er: The up­sides and down­sides of the In­fla­tion Re­duc­tion Act

Last year
Law

Mallinck­rodt con­sid­ers Chap­ter 11 as ‘ad­vanced dis­cus­sions’ con­tin­ue

Last year
Pharma

Flori­da adds ne­glect­ed FOIA re­quests to amend­ed law­suit against FDA over drug im­ports

Last year
Pharma
FDA+
First page Previous page 294295296297298299300 Next page Last page
A service from the Financial Times